Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Doctors Begin New Clinical Trial Treating Cancer with 70p Malaria Drug

By St. George's University of London | March 16, 2017

Source: St. George’s University

Experts from St George’s University of London, and St George’s Hospital have joined forces to investigate whether a common and cheap malaria drug can be used also against cancer.

The researchers and clinicians raised more than £50,000 through a crowdfunding campaign to fund the second part of their trial into whether the drug artesunate can tackle colorectal cancer, and now are recruiting patients to take part in their clinical studies.

In all £54,247 was raised to investigate whether the drug can help cancer patients by reducing the multiplication of tumour cells and decreasing the risk of cancer spreading or recurring after surgery. If it does, the drug could be used to provide a cheaper adjunct to current expensive chemotherapy.

Professor Sanjeev Krishna, an infectious disease expert at St George’s, University of London, who jointly leads the study with Professor Devinder Kumar, a colorectal cancer surgeon based at St George’s Hospital, said: “We are delighted that the next phase of our study is now going ahead and we are looking forward to working with patients to examine whether this important work can have a real impact on cancer patients’ lives.

“Working with colleagues at St George’s Hospital has proved invaluable. Our partnerships will now also include Ashford and St Peter’s University Hospitals and Kingston University Hospital NHS Foundation Trusts so we can speed up the process of recruiting patients and getting the study results.

“Collaborations like this between the academic researchers and clinicians in our leading hospitals are the bedrock of our opportunities to gain understanding and potential breakthroughs in treatment that can benefit many.

“Other centres are also welcome to join if interested in our work, which is now moving into answering the clinically important questions aiming to change practice.”

Researchers worked with supporters from the public, patients, colleagues and charities including Bowel Disease UK and the AntiCancer Fund to support their crowdfunding campaign on FutSci, an organisation that aims to support crowdfunding for research, innovation and technology in the life sciences.

A charity, Bowel Disease UK, started by Gary Douch after he became a patient treated by Professor Kumar donated £200,000 to fund the study.

Professor Kumar, who has been a colorectal cancer surgeon for three decades, added: “We are proud to have set up this pioneering study at St George’s University and St George’s University Hospitals NHS Foundation Trust.

“We hope that this study will help to answer some really important research questions to see if a simple intervention with an established, off-patent and affordable antimalarial drug such as artesunate taken for two weeks before surgery can reduce the risk of cancer recurrence in patients with Stage II/III bowel cancer.

“The overall aim of our research is to improve patient survival and quality of life. Research into repurposing drugs in this way for new disease indications is vital and an excellent use of resources for the NHS.”

Artesunate is derived from the plant Artemisia annua, also known as sweet wormwood. The Chinese scientist Tu Youyou, whose research in the 1960s led to the development of artesunate from a plant used in Chinese traditional medicine, was awarded the Nobel Prize for Medicine in 2015.

More than one million patients are diagnosed with colorectal cancer globally each year. Colorectal cancer is the third most common cancer in men and the second most common cancer in women and is a leading cause of mortality. In the UK, 110 new cases are diagnosed daily, with older patients particularly at risk of death. Current treatments involve complex combinations of surgery, chemotherapy and radiotherapy.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE